A Prospective Study to study the Efficacy and Side Effects of Ormeloxifene in Regression of Mastalgia and Fibroadenoma: Is It the Ideal Drug?
Citation Information :
Gupta N. A Prospective Study to study the Efficacy and Side Effects of Ormeloxifene in Regression of Mastalgia and Fibroadenoma: Is It the Ideal Drug?. J South Asian Feder Obs Gynae 2016; 8 (1):48-56.
Clinical evaluation of Centchroman: a new oral contraceptive. In: Puri CP, VanLook PFa, editors. Hormone antagonists for fertility regulation. Ind Soc Study Reprod Fert, India, Bombay, 1998. p. 223-230.
Centchroman regresses mastalgia: A randomised comparison with Danazol. Ind J Surg 2011 May-Jun;73930:199-205.
Role of centchroman in regression of mastalgia and fibroadenoma. World J Surg 2007;31:1178-1184.
Cyclical mastalgia—is it a manifestation of aberration in lipid metabolism? Ind J Physiol Pharmacol 1994;38:267-271.
Treatment of cyclical mastalgia: results of a randomized, placebo-controlled, double-blind study [translated from German]. Geburtsh Frauenheilk 1997;57:569-574.
Treatment of mastopathy associated with cyclic mastodynia: clinical results and hormone profiles [translated from German]. Gynakol Rundsch 1986;26:65-79.
Prolactin response to thyrotropin-releasing hormone stimulat ion and dopaminergic inhibition in benign breast disease. Cancer 1984;53:1311-1315.
Behaviour of estrogen receptor, histological correlation, and clinical outcome in patients with benign breast disorders. Eur J Surg 2002;168:631-634.
Plasma oestradiol and progesterone in benign breast disease. Eur J Cancer 1973;9:553-556.
Breast pain nodularity. In: Hughes LE, Mansell RE, Webster DJT. Benign Disorders and diseases of the breast: concepts and clinical management. 2nd ed. London: WB Saunders Company; 2000. p. 95-121.
Diagnosis of diseases of the breast. 1st ed. Philadelphia: WB Saunders Company; 1997. p. 385.
Twenty-fourhour preoperative endocrine profiles in women with benign and malignant breast disease. Cancer Res 1977;37:4655-4659.
Serum prolactin concentration on benign breast disease throughout the menstrual cycle. Eur J Cancer 1977;13:597-603.
PRL, TSH and thyroid hormones in benign breast disease. Klin Wochenschr 1981;59:403-407.
Reassurance in the treatment of mastalgia. Breast J 1999;5:162-165.
Sports brassiere: is it a solution for mastalgia? Breast J 2000;6:407-409.
Effects of caffeine free diet on benign breast disease: a randomized trial. Surgery 1982;91:263-267.
Response of fibrocystic disease to caffeine withdrawal and correlation with cyclic nucleotides with breast disease. Am J Obstet Gynecol 1979;135:157
Oral contraceptives and reduced risk of benign breast diseases. N Engl J Med 1976;294:419-422.
A case control study of diet and benign proliferative epithelial disorder of the breast. Cancer Res 1990;50:3176-3181.
A clinical trial of evening primrose oil in mastalgia. Br J Surg 1981;68:801
Evening primrose oil and fish oil for severe chronic mastalgia: a randomized, double blind, controlled trial. Am J Obstet Gynecol 2002;187:1389-1394.
Effect of evening primrose oil on clinically diagnosed fibroadenomas. Breast 2000;9:35-36.
Vitamin E and evening primrose oil for management of cyclical mastalgia: a randomized pilot study. Altern Med Rev 2010;15(1): 59-67.
A double-blind randomized controlled trial of isoflavones in the treatment of cyclical mastalgia. The Breast 2002;11:170-174.
Abnormalities in plasma essential fatty acid levels in women with premenstrual syndrome and with nonmalignant breast disease. J Nutr Med 1991;2:259-264.
Effects and tolerability of n-6 essential fatty acid supplementation in patients with recurrent breast cysts—a randomized doubleblind placebo-controlled trial. J Nutr Med 1990;1:195-200.
Behaviour of estrogen receptor, histological correlation and clinical outcome in patients with benign breast disorder. Eur J Surg 2002;168:631
On behalf of the Efamast study group: a randomized multicenter study of gamolenic acid (Efamast) with and without antioxidant vitamins and minerals in the management of mastalgia. Breast J 2005;11:41-47.
Aberration of normal development and involution: a new perspective on pathogenesis and nomenclature of benign breast disorders. Lancet 1987;11:1316-1319.
Clinical studies with an antigonadotrophin-Danazol. Fertil Steril 1971;22:102-112.
The use of an impeded androgen Danazol in the management of benign breast disorders. Am J Obstet Gynecol 1971;127:130-134.
Maintenance therapy of cyclical mastalgia using low dose Danazol. J R Coll Surg Edinb 1989;34:79-84.
A doubleblind controlled trial of danazol and bromocriptine in the management of severe cyclical breast pain. Br J Clin Pract 1986;40:326-330.
A review of the role of bromocriptine in symptomatic benign breast disease. Res Clin Forum 1981;3:61-63.
Evaluation of the ultrasonographic volume of breast fibroadenomas in women treated with tamoxifen. Minerva Gynecol 2002;54 (6):531-535.
Dosage and duration of tamoxifen for mastalgia: a controlled trial. Br J Surg 1988;75:845-846.
Effect of some non-steroidal antifertility agents on the biochemistry of the uterus and uterine fluids in rats.indian J Exp Biol 1973;11:479-483.
Double-blind controlled trial of tamoxifen therapy for mastalgia. Lancet 1986;8376:287-288.
European randomized, multicenter study of goserelin (Zoladex) in the management of mastalgia. Am J Obstet Gynecol 2004;191:1942-1949.
Risk factor for fibroadenoma: a case control study in Australia. Am J Epidemiol 1992;135:247-258.
An epidemiologic study of breast cancer and benign breast neoplasm in relation to the oral contraceptive and estrogen use. Eur J Cancer 1979;15:395-405.
Fibroadenoma and the use of exogenous hormones: a case control study. Am J Epidemiol 1988;127:454-461.
Evaluation of the ultrasonographic volume of breast fibroadenomas in women treated with tamoxifen. Minerva Gynecol 2002;54: 531-535.